Understanding this mechanism has driven significant advancements in therapeutic strategies, particularly for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) breast cancer, which constitutes approximately 70% of breast cancer cases (Howlader et al., 2014). Here, ERBB2 is linked to breast carcinoma.